Results 91 to 100 of about 2,795 (144)

Non-tuberculous mycobacterial infection in cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor: now is not the time to lower the guard. [PDF]

BMJ Open Respir Res
Evans IES, Smith D, Henderson D, Riddles T, Masel P, Moore V, Burke AJ, Thomson RM, Reid DW.   +8 more
europepmc   +1 more source

The cystic fibrosis airway cytokine interleukin-1β enhances cystic fibrosis transmembrane conductance regulator modulator efficacy. [PDF]

ERJ Open Res
Gentzsch M, Boyles SE, Minges JT, Cholon DM, Okuda K, Ribeiro CMP.   +5 more
europepmc   +1 more source

AI-driven breathomics for early detection of CFTR modulator resistance in cystic fibrosis. [PDF]

Ann Med Surg (Lond)
Khan MH, Tariq AU, Cheema WA, Fatima M.
europepmc   +1 more source

Real-World Impact of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Italy: A Retrospective Study from a Cystic Fibrosis Center. [PDF]

Pulm Ther
Cipolli M, Thorat T, Pafundi PC, Roggeri A, Roggeri DP, Rossi C, Pintani E, Meneghelli I, Lucca F, Fratoni A, Vega-Hernandez G.   +10 more
europepmc   +1 more source

Cystic Fibrosis in the Era of Precision Medicine: Transformative Progress and Persistent Challenges. [PDF]

J Clin Med
Gur M, Bentur L.
europepmc   +1 more source

Colorectal Cancer Complicated by Pulmonary Embolism and Potential Takotsubo Cardiomyopathy in a Person With Cystic Fibrosis: Diagnostic and Management Considerations. [PDF]

Respirol Case Rep
Frederiksen L, Brown J, Moore V, Reid DW.   +3 more
europepmc   +1 more source

Impact of Elexacaftor-Tezacaftor-Ivacaftor on Gastrointestinal Symptoms, Intestinal Ultrasound, and Pancreatic Stiffness in Cystic Fibrosis. [PDF]

Clin Transl Gastroenterol
Fraquelli M, Piagnani A, Corti F, Lanfranchi C, Casazza G, Colombo C.   +5 more
europepmc   +1 more source

L467F;F508del Complex Allele in a Heterozygous State with CFTRdele2,3: What to Expect from CFTR Modulators? [PDF]

Int J Mol Sci
Kondratyeva E, Efremova A, Melyanovskaya Y, Krasnova M, Milovanov M, Shchagina O, Stepanova A, Voronkova A, Sherman V, Kutsev S, Goldshtein D.   +10 more
europepmc   +1 more source

Persistence of lung hyperinflation and small airway dysfunction in school-aged children with cystic fibrosis treated with elexacaftor-tezacaftor-ivacaftor: results from the real-world MODUL-CF study. [PDF]

ERJ Open Res
Colin L, Delaup V, Le Bourgeois M, Neve V, Wizla-Derambure N, Ioan IC, Tatopoulos A, Kieffer S, Blonde A, Bokov P, Houdoin V, Le Clainche L, Barzic A, Ohlmann C, Toin T, Perrin T, Coutier L, Abou Taam R, Bonnel AS, Rignani A, Feghali H, Bui S, Fayon M, Letierce A, Sermet-Gaudelus I, Reix P.   +25 more
europepmc   +1 more source

Impact of elexacaftor/tezacaftor/ivacaftor on gastrointestinal outcomes, inflammation, exocrine pancreatic function and fat malabsorption: Report of PROMISE pediatric substudy. [PDF]

J Cyst Fibros
Green N, Vu P, Xie J, Schwarzenberg SJ, Freedman S, Narkewicz M, Pittman J, Ratjen F, Rosenfeld M, Pope C, Duong J, Hoffman L, Heltshe S, Lusman SS, PROMISE Study Group.   +14 more
europepmc   +1 more source